{"id":"NCT00765999","sponsor":"Forest Laboratories","briefTitle":"An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation","officialTitle":"An Open-Label, Long-Term Safety Study of Oral Linaclotide Administered to Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10-31","primaryCompletion":"2012-01-31","completion":"2012-01-31","firstPosted":"2008-10-03","resultsPosted":"2019-02-15","lastUpdate":"2019-02-15"},"enrollment":1559,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Constipation","Irritable Bowel Syndrome With Constipation"],"interventions":[{"type":"DRUG","name":"Linaclotide","otherNames":["Linzess"]}],"arms":[{"label":"Linaclotide","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).","primaryOutcome":{"measure":"Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"Up to 78 weeks for AEs; within 30 days of last dose of study drug (up to 82 weeks) for serious AEs.","effectByArm":[{"arm":"Linaclotide (CC)","deltaMin":399,"sd":null},{"arm":"Linaclotide (IBS-C)","deltaMin":748,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":118,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":523},"commonTop":["Diarrhoea","Abdominal pain","Upper respiratory tract infection","Sinusitis","Urinary tract infection"]}}